ESMO 2025 | Weekly second-line PTC after immunotherapy progression in HNSCC
Marcelo Bonomi, MD, The Ohio State University, Columbus, OH, examines a retrospective analysis of weekly paclitaxel, carboplatin, and cetuximab (PTC) as second-line therapy for recurrent or metastatic head and neck squamous cell cancer (HNSCC) following progression on prior immunotherapy. More favorable results were observed in those progressing on immunotherapy alone, and weekly PTC had manageable adverse events. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So after immunotherapy became first-line treatment for a patient with recurrent metastatic head and neck cancer, we still don’t know what is the best option to treat for those patients who are going to progress on immunotherapy. So the purpose of this study was to assess if giving cetuximab with low-dose chemo, again, you know, can improve survival in this patient population...
So after immunotherapy became first-line treatment for a patient with recurrent metastatic head and neck cancer, we still don’t know what is the best option to treat for those patients who are going to progress on immunotherapy. So the purpose of this study was to assess if giving cetuximab with low-dose chemo, again, you know, can improve survival in this patient population. So we saw that we see good responses. About 30 to 40 percent of the patients will respond to this therapy in the second line. And we see that the patients who will benefit the most are patients who receive immunotherapy as a single agent in the first line. So those patients really see an overall survival of 10 months, which is kind of a heads up for patients who progress after immunotherapy. So now we are assessing the combination of cetuximab with immunotherapy, continuing with immunotherapy plus cetuximab in the second-line setting, but we are still analyzing that data.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
